{"title":"FAT LOSS","description":"\u003ch2 id=\"tinymce_scroll_sign\"\u003eUnderstanding Fat Loss: Key Strategies and Tips\u003c\/h2\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eWhat Is Fat Loss and Why It Matters\u003c\/h3\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eFat loss is the process of reducing body fat through a combination of diet, exercise, and lifestyle changes. Achieving fat loss is important for improving overall health, boosting energy levels, and reducing the risk of chronic diseases such as diabetes and heart disease. Unlike general weight loss, fat loss focuses specifically on decreasing fat tissue while preserving muscle mass. This balanced approach leads to better body composition and long-term wellness. Understanding how fat loss works can help you make informed decisions and stay motivated on your health journey.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eNutrition Tips to Support Fat Loss\u003c\/h3\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eProper nutrition plays a vital role in effective fat loss. Consuming a balanced diet rich in whole foods, including lean proteins, healthy fats, and plenty of vegetables, helps maintain metabolism and supports fat burning. Cutting back on processed foods, added sugars, and refined carbs reduces excess calorie intake and prevents fat gain. Additionally, staying hydrated and controlling portion sizes are simple yet powerful ways to promote fat loss. Making sustainable changes to your eating habits ensures better success over time.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eExercise Approaches for Optimal Fat Loss\u003c\/h3\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eIncorporating regular exercise boosts fat loss by increasing calorie burn and preserving muscle mass. A combination of cardiovascular workouts and strength training is most effective. Cardio exercises, such as brisk walking, running, or cycling, help burn calories quickly. Strength training builds and maintains muscle tissue, which improves metabolism and enhances fat loss. Consistency and progression in your workout routine are key to seeing lasting results. Remember, choosing activities you enjoy will make it easier to stick with your fitness goals.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","products":[{"product_id":"5-amino-1mq","title":"5-Amino-1MQ","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e5-Amino-1MQ | 5-Amino-1-Methylquinolinium | Selective NNMT Inhibitor | Research Compound\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eFull Name:\u003c\/strong\u003e 5-Amino-1-Methylquinolinium \u003cstrong\u003eAlso Known As:\u003c\/strong\u003e 5-Amino-1MQ, NNMTi \u003cstrong\u003eMechanism:\u003c\/strong\u003e Selective, membrane-permeable inhibitor of Nicotinamide N-Methyltransferase (NNMT) \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₁₀H₁₁N₂⁺ \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 159.21 g\/mol \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 63887-14-9\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is 5-Amino-1MQ?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e5-Amino-1MQ (5-Amino-1-Methylquinolinium) is a small, membrane-permeable synthetic molecule first characterised by researchers at the University of Texas Medical Branch in 2017. It was developed as a selective inhibitor of Nicotinamide N-Methyltransferase (NNMT) — a cytosolic enzyme responsible for methylating nicotinamide using S-adenosylmethionine (SAM) as a methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH) in the process.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWhile technically classified as a small molecule rather than a peptide, 5-Amino-1MQ has rapidly become one of the most actively studied research compounds in the fields of metabolic biology, NAD+ pathway research, and ageing science — and is frequently catalogued alongside research peptides given its overlapping research applications and target audience.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eNNMT is expressed at high levels in white adipose tissue, liver, skeletal muscle, brain, kidney, heart, and lung — and its expression increases markedly with age in muscle tissue, with one study reporting approximately three-fold higher NNMT protein expression in aged versus young muscle. Elevated NNMT activity has been consistently linked to metabolic dysfunction, obesity, insulin resistance, sarcopenia, and impaired NAD+ availability. By selectively inhibiting this enzyme, 5-Amino-1MQ disrupts a key metabolic bottleneck, redirecting nicotinamide flux back toward NAD+ synthesis via the salvage pathway — a mechanism that has generated substantial scientific interest across multiple research disciplines.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eA critical advantage of 5-Amino-1MQ over many earlier NNMT inhibitors is its high membrane permeability. Confirmed by both PAMPA assay and bidirectional Caco-2 cell transport studies, this property enables the compound to cross cellular membranes effectively — a prerequisite for intracellular NNMT engagement that earlier inhibitors in this class lacked. Importantly, 5-Amino-1MQ has demonstrated high selectivity for NNMT, with preclinical data showing it does not inhibit related SAM-dependent methyltransferases or other enzymes in the NAD+ salvage pathway.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur 5-Amino-1MQ is manufactured under rigorous quality-controlled conditions, verified to a purity of greater than 99% by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS), and supplied as a lyophilised powder for maximum stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Scientific Interest\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e5-Amino-1MQ has accumulated a compelling body of preclinical evidence since its introduction, spanning metabolic biology, skeletal muscle research, adipose tissue science, cardiovascular biology, and oncology. Its position at the intersection of NAD+ metabolism, methyl-donor homeostasis, and sirtuin signalling makes it one of the most mechanistically versatile research compounds currently available.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eThe NNMT-NAD+ Axis: Core Mechanism\u003c\/strong\u003e NNMT occupies a critical node in cellular metabolic regulation by consuming nicotinamide — the primary substrate for NAD+ biosynthesis via the salvage pathway — and diverting it toward methylated metabolite production. When NNMT activity is elevated, as it is in obesity, ageing, and metabolic disease states, intracellular NAD+ levels decline. This depletion has cascading downstream consequences: reduced sirtuin (SIRT1, SIRT3) activity, impaired mitochondrial function, disrupted energy sensing, and increased cellular senescence. By inhibiting NNMT, 5-Amino-1MQ preserves nicotinamide availability for NAD+ synthesis via nicotinamide mononucleotide (NMN), effectively boosting intracellular NAD+ without the need to supply exogenous NAD+ precursors. In vitro studies have confirmed that 5-Amino-1MQ treatment significantly increases intracellular NAD+ levels in both adipocyte and hepatocyte cell models.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAdipose Tissue \u0026amp; Obesity Research\u003c\/strong\u003e The most extensively documented preclinical research on 5-Amino-1MQ concerns its effects in adipose tissue and diet-induced obesity models. In a landmark study published in Biochemical Pharmacology, obese mice treated with 5-Amino-1MQ demonstrated significant reductions in body weight, white adipose tissue mass, and adipocyte size relative to vehicle-treated controls — achieving body composition parameters comparable to lean control animals. These changes occurred without significant reduction in food intake, suggesting the effects were driven by increased energy expenditure rather than appetite suppression. In vitro, 5-Amino-1MQ suppressed lipogenesis and reduced intracellular 1-MNA levels in differentiated adipocytes, providing mechanistic support for the in vivo findings.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eInsulin Sensitivity \u0026amp; Glucose Metabolism\u003c\/strong\u003e Parallel to its effects on fat mass, 5-Amino-1MQ has been studied in models of insulin resistance and type 2 diabetes. Preclinical data in diet-induced obese mouse models demonstrated marked improvements in insulin sensitivity, with one study observing reductions in serum insulin levels of 50–60% alongside normalisation of glucose tolerance and fasting blood glucose. These findings are consistent with the known role of NNMT in adipose tissue insulin signalling and have led researchers to position NNMT inhibition — and 5-Amino-1MQ specifically — as a mechanistically novel and complementary approach to existing metabolic disease research tools.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSkeletal Muscle \u0026amp; Sarcopenia Research\u003c\/strong\u003e A significant and rapidly expanding body of literature has examined 5-Amino-1MQ in models of skeletal muscle ageing and regeneration. NNMT expression increases approximately three-fold in aged versus young muscle tissue, and this overexpression has been identified as a dominant component of the gene expression signature for sarcopenia. Elevated NNMT activity in aged muscle is associated with impaired NAD+ availability, dysregulated SIRT1 activity, and increased muscle stem cell (satellite cell; MuSC) senescence — all contributors to the decline in regenerative capacity that characterises ageing muscle.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIn a pivotal study examining aged mouse models of muscle injury, NNMT inhibitor treatment with 5-Amino-1MQ rescued muscle stem cell function, producing nearly two-fold greater cross-sectional area (CSA) in regenerated myofibres and significantly shifting fibre size distribution toward larger, functionally superior fibres compared to untreated controls. Contractile force in healed muscle was approximately 70% greater in the 5-Amino-1MQ treated group.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eA subsequent 2024 study published in Scientific Reports (University of Texas Medical Branch) directly compared exercise training alone versus exercise training combined with 5-Amino-1MQ in aged mice. The addition of 5-Amino-1MQ to the exercise protocol produced approximately 150% increases in daily running distance that were sustained over the study period — compared to an initial 75% increase that tapered significantly with exercise alone. Grip strength improvements also exceeded those achieved by exercise training in isolation, leading researchers to describe 5-Amino-1MQ as producing additive effects beyond exercise through mechanistic pathways distinct from training adaptation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMethyl-Donor Metabolism \u0026amp; Epigenetic Research\u003c\/strong\u003e NNMT's consumption of SAM — the universal methyl donor — places it at the centre of epigenetic regulation as well as metabolic biology. When NNMT is overactive, SAM availability for other methyltransferases is reduced, potentially disrupting DNA methylation, histone methylation, and other epigenetically regulated processes. 5-Amino-1MQ, by inhibiting NNMT, preserves SAM availability for these competing methylation reactions. This intersection of metabolic and epigenetic regulation has made NNMT — and by extension, 5-Amino-1MQ — a subject of growing interest in ageing biology and epigenetic research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCardiovascular Research\u003c\/strong\u003e NNMT's role in cardiovascular pathophysiology has become an active area of research, with the enzyme's upregulation linked to atherosclerosis, hypertension, and myocardial ischaemia through multiple pathways. NNMT-mediated NAD+ depletion impairs sirtuin activity and mitochondrial antioxidant defences, while elevated homocysteine levels resulting from SAH accumulation activate pro-inflammatory cascades including TLR4–NF-κB and STAT3–IL-1β signalling. A 2025 review in Biomolecules identified 5-Amino-1MQ as one of the leading candidate NNMT inhibitors for cardiovascular therapeutic research, noting its selectivity and membrane permeability as key pharmacological advantages. No clinical trials in cardiovascular disease have yet been conducted with NNMT inhibitors, making this an open and compelling frontier for preclinical research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eOncology Research\u003c\/strong\u003e Emerging preclinical evidence suggests NNMT plays a role in tumour biology. NNMT overexpression has been observed in several cancer types, and its activity has been linked to epithelial-mesenchymal transition (EMT), tumour stroma remodelling, and enhanced migratory and invasive capacity in cancer cell lines. While 5-Amino-1MQ has not been the primary tool in all oncology-focused NNMT studies, the mechanistic connection between NNMT activity and cancer-associated metabolic reprogramming has positioned NNMT inhibition as an area of growing research interest in experimental oncology.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCompound\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5-Amino-1MQ (5-Amino-1-Methylquinolinium)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eClass\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSelective NNMT inhibitor (small molecule)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eC₁₀H₁₁N₂⁺\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e159.21 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile water or DMSO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMembrane Permeability\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eHigh (confirmed by PAMPA and Caco-2 assay)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSelectivity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eHigh — does not inhibit related SAM-dependent methyltransferases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e63887-14-9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our 5-Amino-1MQ undergoes a comprehensive quality control process prior to release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms compound purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity and structural integrity\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFull batch traceability is maintained across synthesis, purification, and quality testing, giving researchers the confidence required for reproducible and reliable experimental work.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e5-Amino-1MQ lyophilised powder is soluble in sterile water or DMSO, depending on the experimental protocol. For aqueous reconstitution, gently swirl in sterile bacteriostatic water until fully dissolved. If using DMSO, ensure downstream dilution into aqueous buffer is performed to maintain cell viability in cell-based assays. Once reconstituted, aliquot immediately and store at –20°C. Avoid repeated freeze-thaw cycles to preserve compound integrity and experimental reproducibility.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e5-Amino-1MQ in Context: Relationship to Other Catalogue Compounds\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e5-Amino-1MQ occupies a distinctive and complementary position within our research catalogue. Its mechanism — NNMT inhibition leading to elevated intracellular NAD+ — places it in a direct functional relationship with MOTS-c, which operates at the level of mitochondrial signalling and AMPK activation. Both compounds converge on cellular energy metabolism and represent complementary tools for researchers studying metabolic ageing and bioenergetics from different mechanistic angles.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFor researchers working on metabolic dysfunction, 5-Amino-1MQ also provides a mechanistically distinct perspective relative to the receptor-level hormonal signalling approach of retatrutide. While retatrutide acts systemically via GIP, GLP-1, and glucagon receptors to modulate energy homeostasis, 5-Amino-1MQ operates intracellularly — directly at the level of NAD+ availability and methyl-donor metabolism — offering researchers a complementary tool for multi-pathway metabolic research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll compounds in our catalogue are manufactured to the same \u0026gt;99% purity standard and are supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. 5-Amino-1MQ has not entered clinical trials and is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"5mg","offer_id":59643105050958,"sku":null,"price":28.99,"currency_code":"GBP","in_stock":true},{"title":"50mg","offer_id":59643105083726,"sku":null,"price":78.88,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/5-amino-1mq-navy-v2.jpg?v=1781523569"},{"product_id":"bacteriostatic-water-bac-water","title":"Bacteriostatic Water (BAC Water)","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eBacteriostatic Water | BAC Water | Sterile Peptide Reconstitution Solution | Research Grade\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eComposition:\u003c\/strong\u003e Sterile water for injection + 0.9% benzyl alcohol (9 mg\/mL) \u003cstrong\u003eGrade:\u003c\/strong\u003e Research grade — sterile, pyrogen-free \u003cstrong\u003ePreservative:\u003c\/strong\u003e Benzyl alcohol 0.9% (v\/v) \u003cstrong\u003epH:\u003c\/strong\u003e 4.5–7.0 \u003cstrong\u003eAppearance:\u003c\/strong\u003e Clear, colourless solution \u003cstrong\u003ePackaging:\u003c\/strong\u003e Sealed multi-dose vials \u003cstrong\u003eStorage:\u003c\/strong\u003e Room temperature (15–25°C), away from light; refrigerate after opening\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is Bacteriostatic Water?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBacteriostatic water (BAC water) is a preparation of sterile water for injection containing 0.9% benzyl alcohol (9 mg\/mL) as a preservative. The term \"bacteriostatic\" refers to the benzyl alcohol component — a broad-spectrum antimicrobial agent that inhibits bacterial growth and multiplication within the vial, without necessarily killing bacteria outright. This preservative action allows BAC water to remain safely usable across multiple withdrawals over an extended period — a critical property that distinguishes it from standard sterile water for injection, which is intended for single-use only and carries no microbial protection after the vial seal is first broken.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBAC water is the standard reconstitution vehicle for a wide range of lyophilised research peptides, proteins, and biological compounds — including human growth hormone (HGH), GHRFs, GHRPs, and most synthetic research peptides. It is used wherever a multi-dose reconstitution protocol is required, and where peptide or protein stability across multiple draw-down events must be maintained without microbial contamination risk.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur bacteriostatic water is manufactured to research grade: sterile, pyrogen-free, and packaged in sealed multi-dose vials with halogenated butyl stoppers compatible with standard research syringes and needle gauges.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhy BAC Water Matters for Peptide Research\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe choice of reconstitution vehicle is one of the most practically consequential decisions in peptide research — and one that is frequently underestimated. Using an inappropriate reconstitution solution can compromise peptide stability, alter solubility, affect experimental reproducibility, and — in the case of multi-dose vials — introduce microbial contamination that invalidates results and degrades the compound.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBacteriostatic water addresses these concerns by providing a chemically inert, pH-appropriate, sterile environment with sustained antimicrobial protection across repeated vial access events. For researchers working with lyophilised peptides that require reconstitution before use — including every compound in our research catalogue — BAC water is the most broadly appropriate and widely used reconstitution vehicle in the scientific literature.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCompatibility with our catalogue:\u003c\/strong\u003e BAC water is the recommended reconstitution vehicle for HGH (somatotropin), tesamorelin, BPC-157, TB-500, MOTS-c, Selank, and the majority of other lyophilised research peptides. GHK-Cu is optimally reconstituted in sterile water or PBS, and 5-Amino-1MQ may require DMSO for certain protocols — but for the majority of peptide reconstitution applications, BAC water is the first-choice solution.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eComposition \u0026amp; Technical Specifications\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eWhy 0.9% benzyl alcohol?\u003c\/strong\u003e Benzyl alcohol has been used as an antimicrobial preservative in injectable preparations since the 1920s. At 0.9% concentration, it provides effective bacteriostatic activity against a broad spectrum of gram-positive and gram-negative bacteria — the most likely contaminants in a multi-access vial environment — while remaining chemically compatible with the widest range of peptides, proteins, and hormones used in research. Higher benzyl alcohol concentrations can begin to affect protein folding and stability; 0.9% represents the established standard for balancing preservation efficacy with compound compatibility.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eWhy not sterile water for injection?\u003c\/strong\u003e Standard sterile water for injection (SWFI) contains no preservative and is intended for single-use only. Once the seal is broken and the vial accessed, SWFI provides no protection against bacterial contamination from subsequent needle insertions. For researchers who routinely draw multiple aliquots from a single reconstituted vial over days or weeks — as is standard practice with peptide research compounds — SWFI is inappropriate and significantly increases the risk of microbial contamination that will degrade the compound and compromise experimental results.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eWhy not saline or PBS?\u003c\/strong\u003e Normal saline (0.9% sodium chloride) and phosphate-buffered saline (PBS) are appropriate for some peptide reconstitution applications but carry important caveats. Saline can reduce the solubility of certain peptides and proteins and provides no preservative action in multi-dose vials. PBS introduces phosphate and salt ions that can interact with some peptides and alter their behaviour in downstream assays. For most lyophilised research peptide applications, BAC water provides a cleaner, more universally compatible, and more practically convenient reconstitution vehicle.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eBAC Water and Peptide Stability\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eProper reconstitution practice is as important as purity when it comes to preserving the integrity and research utility of lyophilised peptides. The following principles apply to reconstitution with BAC water across the research peptide catalogue:\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eTechnique:\u003c\/strong\u003e Always inject BAC water slowly against the side of the vial — never directly onto the lyophilised powder, which can mechanically disrupt peptide structure. Swirl gently until dissolved; do not shake or vortex.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eTemperature:\u003c\/strong\u003e Allow the lyophilised vial to reach room temperature before reconstitution. Cold powder reconstituted with room-temperature water can produce localised concentration gradients that slow dissolution.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eStorage after reconstitution:\u003c\/strong\u003e Reconstituted peptides in BAC water should be stored at 2–8°C (refrigerated). The benzyl alcohol preservative protects against microbial growth but does not prevent peptide degradation from heat or light exposure. Reconstituted solutions should be used within the timeframes recommended for each specific compound — typically 28 days for HGH and tesamorelin, and up to 30 days for shorter synthetic peptides, though this varies by compound.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eFreeze-thaw:\u003c\/strong\u003e Reconstituted peptide solutions in BAC water should not be re-frozen unless the specific compound's data sheet indicates this is acceptable. For long-term storage, lyophilise in advance of reconstitution or aliquot before the first freeze-thaw cycle.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eComposition\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWater for injection + 0.9% benzyl alcohol (9 mg\/mL)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eGrade\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eResearch grade — sterile, pyrogen-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePreservative\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eBenzyl alcohol 0.9% (v\/v)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003epH\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e4.5–7.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eOsmolality\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e~9 mOsm\/kg (hypotonic)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eClear, colourless solution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePackaging\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSealed multi-dose vials with halogenated butyl stopper\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eRoom temperature (15–25°C), away from light; refrigerate after opening\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAs labelled on vial; discard 28 days after first opening\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur bacteriostatic water is manufactured to research-grade standards:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eSterility Testing\u003c\/strong\u003e — confirmed sterile, free from viable microorganisms\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePyrogen \/ Endotoxin Testing\u003c\/strong\u003e — confirmed pyrogen-free by LAL (Limulus Amebocyte Lysate) assay\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eBenzyl Alcohol Content\u003c\/strong\u003e — verified at 0.9% (9 mg\/mL) by validated assay\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003epH Verification\u003c\/strong\u003e — confirmed within the 4.5–7.0 range\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eParticulate Matter Testing\u003c\/strong\u003e — confirmed free from visible particulates\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eEssential Accessory for Every Peptide Researcher\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBAC water is a consumable that every serious research peptide laboratory requires. We recommend maintaining an adequate supply to support your full research protocol — running out mid-study and substituting an alternative reconstitution vehicle can introduce a variable that undermines experimental comparability. Given the investment represented by high-purity research peptides, using a matched, research-grade reconstitution solution is a straightforward way to protect that investment and maintain the integrity of your experimental data.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIf you are purchasing any lyophilised peptide from our catalogue — whether BPC-157, TB-500, GHK-Cu, MOTS-c, Selank, tesamorelin, HGH, retatrutide, or any other compound — we recommend including bacteriostatic water in your order.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for research and laboratory use only. Bacteriostatic water containing benzyl alcohol is not approved for use in neonates or premature infants, in whom benzyl alcohol toxicity has been documented at high doses. This product must not be self-administered or used outside of appropriately supervised research or clinical contexts. By purchasing this product, the buyer confirms they are a qualified researcher and will use it solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"10ml","offer_id":59643105149262,"sku":null,"price":7.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/bac-water-navy-v2.jpg?v=1781523530"},{"product_id":"cjc-1295-no-dac","title":"CJC-1295 No DAC","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eCJC-1295 No DAC | Modified GRF (1-29) | Tetrasubstituted GHRH Analogue | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAlso Known As:\u003c\/strong\u003e Modified GRF (1-29), Mod GRF 1-29, CJC-1295 without DAC, tetrasubstituted GRF (1-29) \u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₁₅₂H₂₅₂N₄₄O₄₂ \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 3367.97 g\/mol \u003cstrong\u003eKey Substitutions:\u003c\/strong\u003e D-Ala² | Gln⁸ | Ala¹⁵ | Leu²⁷ (tetrasubstituted) \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 863288-34-0\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is CJC-1295 No DAC?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eCJC-1295 No DAC — formally known as Modified GRF (1-29), and sometimes abbreviated Mod GRF 1-29 — is a synthetic 29-amino acid analogue of endogenous growth hormone-releasing hormone (GHRH), engineered to deliver enhanced metabolic stability and sustained GHRH receptor activity while preserving the physiologically important pulsatile pattern of growth hormone secretion.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTo understand CJC-1295 No DAC, it helps to understand the problem it was designed to solve. Endogenous GHRH is a 44-amino acid hypothalamic peptide that triggers GH release from anterior pituitary somatotrophs. However, the native molecule is rapidly degraded in circulation — primarily by the serum enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves at the Tyr-Ala bond at the N-terminus — resulting in a biological half-life of just two to seven minutes. This extreme brevity makes native GHRH largely impractical as a sustained research tool.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe first step toward a solution was GRF (1-29), also known as sermorelin — a truncated 29-amino acid fragment of GHRH that retains full receptor binding and biological activity, as the first 29 residues contain the complete pharmacophore for GHRH receptor activation. Modified GRF (1-29) — CJC-1295 No DAC — takes this a step further through four targeted amino acid substitutions at positions 2, 8, 15, and 27 of the GRF (1-29) sequence:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePosition 2:\u003c\/strong\u003e L-alanine → D-alanine — provides primary protection against DPP-4 enzymatic cleavage at the N-terminus\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePosition 8:\u003c\/strong\u003e Asparagine → Glutamine — reduces oxidative instability during manufacture and storage\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePosition 15:\u003c\/strong\u003e Glycine → Alanine — enhances structural rigidity and reduces conformational susceptibility to peptidase activity\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePosition 27:\u003c\/strong\u003e Methionine → Leucine — eliminates a methionine oxidation site, significantly improving chemical stability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThese four substitutions collectively elevate the half-life of Modified GRF (1-29) from the two-to-seven minute range of native GHRH to approximately 30 minutes — long enough to produce a meaningful GH secretory pulse while remaining short enough to preserve the physiologically important pulsatile pattern of GH release and maintain hypothalamic-pituitary feedback regulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eA critical nomenclature note for researchers:\u003c\/strong\u003e The term \"CJC-1295\" in the scientific literature formally refers to CJC-1295 DAC — the albumin-binding, long-acting form of the compound developed by ConjuChem Biotechnologies, which carries an additional Drug Affinity Complex (DAC) modification enabling covalent binding to serum albumin and producing a half-life of approximately six to eight days. \"CJC-1295 No DAC\" or \"CJC-1295 without DAC\" is a widely used commercial synonym for Modified GRF (1-29) — and while this nomenclature is ubiquitous in the research peptide community, it is important for researchers to recognise that these are pharmacologically distinct compounds with substantially different pharmacokinetic profiles and experimental implications.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur CJC-1295 No DAC is synthesised under strict quality-controlled manufacturing conditions and verified to a purity of greater than 99% by HPLC and Mass Spectrometry. It is supplied as a lyophilised (freeze-dried) powder for maximum stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Scientific Interest\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eCJC-1295 No DAC (Modified GRF 1-29) has been studied as a GHRH-axis research tool in the context of growth hormone secretion, GH\/IGF-1 axis biology, metabolic regulation, body composition, and somatopause research. Its primary scientific value lies in its ability to amplify physiological pulsatile GH secretion — making it a valuable tool for researchers seeking to study the effects of GHRH receptor activation and downstream GH\/IGF-1 signalling under conditions that preserve normal hormonal feedback architecture.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGHRH Receptor Activation \u0026amp; Pulsatile GH Secretion\u003c\/strong\u003e CJC-1295 No DAC binds with high affinity to the GHRH receptor (GHRH-R) — a class B G protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Receptor binding activates the adenylate cyclase–cAMP–PKA intracellular signalling cascade, stimulating both acute GH secretion and GH gene transcription. Because the compound's half-life of approximately 30 minutes is short relative to the natural inter-pulse interval of GH secretion (typically 90–180 minutes), CJC-1295 No DAC produces discrete GH pulses that mimic the physiological secretory pattern rather than creating sustained GH elevation. This pulsatile character is considered experimentally important: the liver and peripheral tissues respond differently to pulsatile versus continuous GH exposure, and several of GH's anabolic and lipolytic effects are specifically dependent on the pulse pattern rather than mean concentration. Researchers studying the distinction between physiological and pharmacological GH signalling will find this a meaningful design consideration in protocol selection.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCJC-1295 No DAC vs. Tesamorelin: Pharmacokinetic Research Design Considerations\u003c\/strong\u003e Both CJC-1295 No DAC and tesamorelin are stabilised GHRH analogues that act at the GHRH receptor to stimulate pulsatile GH secretion — and they are frequently compared by researchers selecting between them. The key differences are structural and pharmacokinetic. Tesamorelin is a 44-amino acid analogue of full-length GHRH, stabilised by an N-terminal trans-3-hexenoic acid modification and carrying a half-life of approximately 30–40 minutes. CJC-1295 No DAC is a tetrasubstituted 29-amino acid fragment with a half-life of approximately 30 minutes. Both produce physiologically comparable pulsatile GH release patterns and preserve feedback regulation. Tesamorelin carries the more extensive clinical validation dataset — including FDA approval and large Phase III trial data — while CJC-1295 No DAC is more widely used as a general-purpose GHRH-axis research tool given its broader availability and established use in the preclinical literature. Both are available in our catalogue, allowing researchers to select the most appropriate compound for their experimental model. Tesamorelin is generally preferred when clinical translatability or regulatory alignment is a research priority; CJC-1295 No DAC is appropriate for preclinical mechanistic studies of the GHRH-GH-IGF-1 axis.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCJC-1295 No DAC vs. CJC-1295 DAC: Key Research Design Distinction\u003c\/strong\u003e The choice between CJC-1295 No DAC and CJC-1295 DAC is one of the most consequential protocol decisions in GHRH-axis research, yet it is frequently confused — including, as noted above, in some published scientific literature. CJC-1295 No DAC produces a ~30 minute half-life with discrete pulsatile GH secretion. CJC-1295 DAC — through its albumin-binding Drug Affinity Complex — achieves a half-life of approximately six to eight days, producing sustained GH elevation across a prolonged period and blunting the natural pulse architecture. These are fundamentally different experimental conditions. Researchers studying physiological GH pulsatility, natural feedback dynamics, or acute GHRH receptor pharmacology should use CJC-1295 No DAC. Researchers studying the effects of sustained GH elevation, or requiring a long-acting dosing interval, should use CJC-1295 DAC. Using the wrong compound for the experimental question is a meaningful source of variability and potential error in GH-axis research design.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGH\/IGF-1 Axis \u0026amp; Anabolic Signalling Research\u003c\/strong\u003e As a GHRH receptor agonist, CJC-1295 No DAC elevates GH secretion, which in turn drives hepatic and peripheral IGF-1 production. IGF-1 — acting through the IGF-1 receptor and downstream PI3K–Akt–mTOR and MAPK signalling cascades — mediates the principal anabolic, growth-promoting, and tissue-remodelling effects of the GH\/IGF-1 axis. Preclinical research has examined CJC-1295 No DAC (and related GHRH analogues) in models of skeletal muscle protein synthesis, lean mass accretion, adipose tissue lipolysis, bone mineral density, and collagen synthesis — with IGF-1 elevation identified as the primary mediator of these downstream effects.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMetabolic \u0026amp; Body Composition Research\u003c\/strong\u003e Growth hormone directly stimulates lipolysis in adipose tissue via hormone-sensitive lipase activation, and indirectly promotes lean mass accrual through IGF-1-mediated protein synthesis and nitrogen retention. CJC-1295 No DAC's amplification of pulsatile GH secretion has made it a useful tool in preclinical studies examining these metabolic effects, including models of age-related body composition change and GH deficiency states. The compound's preservation of pulsatile GH dynamics is particularly relevant in this context, as the lipolytic effects of GH are known to be pulse-amplitude-dependent.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSomatopause \u0026amp; Ageing Research\u003c\/strong\u003e The progressive decline in GHRH output and GH pulsatility with age — somatopause — produces a characteristic pattern of metabolic deterioration including increased visceral adiposity, reduced lean mass, and impaired tissue repair capacity. CJC-1295 No DAC, as a tool for restoring GHRH receptor stimulation and augmenting pulsatile GH output, has been studied in preclinical models of somatopause-associated metabolic change. Its mechanism of action — upstream stimulation of pituitary GH secretion rather than exogenous GH replacement — preserves the regulatory architecture of the hypothalamic-pituitary axis, making it a pharmacologically distinct tool from direct rhGH administration in ageing research models.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCombination Research with GHRPs\u003c\/strong\u003e CJC-1295 No DAC is frequently studied in combination with growth hormone-releasing peptides (GHRPs) — including ipamorelin, GHRP-2, and GHRP-6 — in preclinical research protocols. GHRPs act at the ghrelin receptor (GHSR-1a) to amplify GH secretion through a distinct and mechanistically complementary pathway from GHRH receptor activation. The combination of a GHRH analogue (CJC-1295 No DAC) with a GHRP is known to produce synergistic GH release substantially exceeding the effect of either compound alone — a finding consistent with the known synergistic relationship between the GHRH and ghrelin pathways in regulating pituitary GH secretion. This combination approach has become one of the most common experimental paradigms in preclinical GH-axis research and is an important consideration for researchers designing multi-peptide studies.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCJC-1295 No DAC (Modified GRF 1-29)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAlso Known As\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMod GRF 1-29, Modified GRF (1-29), CJC-1295 without DAC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSequence\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eKey Substitutions\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eD-Ala² \/ Gln⁸ \/ Ala¹⁵ \/ Leu²⁷\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eC₁₅₂H₂₅₂N₄₄O₄₂\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e3367.97 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile bacteriostatic water or PBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eApproximate Half-Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e~30 minutes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e863288-34-0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our CJC-1295 No DAC undergoes a rigorous multi-stage quality control process before release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, correct tetrasubstitution pattern, and full 29-residue sequence accuracy\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFull batch traceability is maintained across synthesis, purification, and quality testing. The four amino acid substitutions are analytically critical features of Modified GRF (1-29) — our MS verification process explicitly confirms the correct substitution pattern to distinguish it from native GRF (1-29) or sermorelin, and to ensure research-grade accuracy.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eCJC-1295 No DAC lyophilised powder should be reconstituted using sterile bacteriostatic water. Inject the water slowly against the side of the vial — not directly onto the powder — and swirl gently until fully dissolved. Do not vortex. Once reconstituted, aliquot and store at 2–8°C. Use within 28–30 days of reconstitution. Avoid repeated freeze-thaw cycles to preserve peptide integrity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eCJC-1295 No DAC Within the Research Peptide Catalogue\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eCJC-1295 No DAC occupies the GHRH secretagogue position within our GH-axis research toolkit. Together with tesamorelin (a 44-residue GHRH analogue with FDA validation) and recombinant human growth hormone (rhGH, the direct GH replacement standard), it provides researchers with three mechanistically distinct points of entry into GH\/IGF-1 axis research: upstream GHRH stimulation with pulsatile GH output (CJC-1295 No DAC and tesamorelin), and direct exogenous GH replacement (rhGH).\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWithin the broader catalogue, CJC-1295 No DAC's GH\/IGF-1 axis effects are mechanistically distinct from — and complementary to — the tissue-repair focus of BPC-157 and TB-500, the dermal and genomic biology of GHK-Cu, the mitochondrial metabolic signalling of MOTS-c, the systemic hormonal triple agonism of retatrutide, the intracellular NAD+ axis of 5-Amino-1MQ, and the neuropeptide biology of Selank. Together, these compounds represent a catalogue spanning the most actively researched peptide mechanisms in contemporary preclinical science.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides are manufactured to the same \u0026gt;99% purity standard and supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. CJC-1295 No DAC (Modified GRF 1-29) is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"5mg","offer_id":59643105345870,"sku":null,"price":19.99,"currency_code":"GBP","in_stock":true},{"title":"10mg","offer_id":59643105378638,"sku":null,"price":33.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/cjc-1295-navy-v2.jpg?v=1781523194"},{"product_id":"ipamorelin","title":"Ipamorelin","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eIpamorelin | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ | Selective GHS-R1a Agonist | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Aib-His-D-2-Nal-D-Phe-Lys-NH₂ \u003cstrong\u003eClassification:\u003c\/strong\u003e Synthetic pentapeptide — selective growth hormone secretagogue receptor 1a (GHS-R1a) agonist \/ GHRP \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₃₈H₄₉N₉O₅ \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 711.85 g\/mol \u003cstrong\u003eKey Structural Features:\u003c\/strong\u003e α-aminoisobutyric acid (Aib) at position 1; D-2-naphthylalanine (D-2-Nal) at position 3; D-phenylalanine (D-Phe) at position 4 \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 170851-70-4\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is Ipamorelin?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin is a synthetic pentapeptide growth hormone-releasing peptide (GHRP) and selective agonist of the ghrelin receptor (GHS-R1a), originally developed by Novo Nordisk in Denmark and first characterised in a landmark 1998 paper in the European Journal of Endocrinology by Raun and colleagues. It was derived from GHRP-1 through a systematic chemistry programme that identified active analogues lacking the central Ala-Trp dipeptide of the parent compound, ultimately yielding ipamorelin as the most pharmacologically refined member of its series.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin's significance in the research peptide landscape rests on a single, defining characteristic: it is the first growth hormone-releasing peptide receptor agonist to demonstrate a selectivity for GH release comparable to that of endogenous GHRH itself. All earlier GHRPs — including GHRP-2 and GHRP-6 — stimulated GH release but also produced dose-dependent elevations in ACTH and cortisol through activation of broader stress-response signalling pathways. Ipamorelin does not. In the foundational Novo Nordisk pharmacology studies, ipamorelin failed to elevate ACTH or cortisol at doses more than 200-fold above its ED50 for GH release — a specificity profile that had not previously been achieved with any GHRP receptor agonist and that fundamentally changed the landscape of GH secretagogue research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eStructurally, ipamorelin incorporates three key non-natural amino acid features that underpin its selectivity and metabolic stability. The α-aminoisobutyric acid (Aib) residue at position 1 confers resistance to N-terminal peptidase cleavage. The D-2-naphthylalanine (D-2-Nal) at position 3 — a bulky, non-natural amino acid — provides critical receptor binding contributions and contributes to selectivity. The D-phenylalanine (D-Phe) at position 4 further stabilises the receptor-bound conformation. Together, these modifications produce a compound with substantially lower systemic plasma clearance than GHRP-6 — approximately five-fold lower — and moderate resistance to metabolic degradation, resulting in a more sustained and reproducible GH secretory response.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin stimulates pulsatile GH secretion from anterior pituitary somatotrophs by acting at the ghrelin receptor (GHS-R1a) — a distinct and mechanistically complementary pathway to the GHRH receptor pathway through which CJC-1295 No DAC and tesamorelin operate. This mechanistic distinction is the basis of the well-established synergistic relationship between ipamorelin and GHRH analogues in GH secretion research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur ipamorelin is synthesised under rigorous quality-controlled manufacturing conditions, verified to a purity of greater than 99% by HPLC and Mass Spectrometry, and supplied as a lyophilised (freeze-dried) powder for maximum stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Scientific Interest\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin has accumulated a rich and diverse body of preclinical research since its characterisation in 1998, spanning GH secretagogue pharmacology, metabolic biology, bone mineral density, gastrointestinal motility, and body composition research. Its defining selectivity profile has made it the reference compound of choice for ghrelin receptor agonism research where hormonal specificity is a priority experimental requirement.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGHS-R1a Receptor Pharmacology \u0026amp; Selectivity\u003c\/strong\u003e Ipamorelin's receptor pharmacology was comprehensively characterised in the original Novo Nordisk studies. In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy closely comparable to GHRP-6 — achieving an EC50 of 1.3 ± 0.4 nmol\/L and an Emax of 85 ± 5% relative to GHRP-6's 100% reference maximum. In vivo, in conscious swine — a model with GH axis pharmacology closely reflective of human GH secretion — ipamorelin produced an ED50 of 2.3 ± 0.03 nmol\/kg and an Emax of 65 ± 0.2 ng GH\/mL plasma, comparable to GHRP-6 (ED50 3.9 ± 1.4 nmol\/kg, Emax 74 ± 7 ng\/mL) but with substantially superior selectivity. Critically, pharmacological profiling using both GHRP receptor antagonists and GHRH antagonists confirmed that ipamorelin stimulates GH release exclusively via the GHRP\/ghrelin receptor pathway — the same receptor used by GHRP-2 and GHRP-6 — rather than through the GHRH receptor. This orthogonal mechanism is the mechanistic basis of the synergistic GH release observed when ipamorelin is combined with GHRH analogues such as CJC-1295 No DAC.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eHormonal Selectivity: No ACTH, Cortisol, Prolactin or Gonadotropin Elevation\u003c\/strong\u003e The most scientifically significant finding in the ipamorelin pharmacology literature is its hormonal selectivity profile. In the definitive swine selectivity study, none of the GH secretagogues tested — including ipamorelin, GHRP-6, and GHRP-2 — affected FSH, LH, prolactin, or TSH levels. However, administration of both GHRP-6 and GHRP-2 produced significant elevations in plasma ACTH and cortisol. Ipamorelin produced no significant elevation in ACTH or cortisol at any dose tested — including doses exceeding 200-fold the GH-releasing ED50. This was described by the original authors as \"very surprising\" and represented a categorically different selectivity profile from all previously characterised GHRP receptor agonists. The practical research implication is substantial: studies using ipamorelin to investigate GH\/IGF-1 axis effects are not confounded by concurrent activation of the hypothalamic-pituitary-adrenal (HPA) axis — a major experimental advantage over GHRP-2 and GHRP-6 in any protocol where cortisol or ACTH are outcome variables, or where HPA axis activation would represent an uncontrolled experimental variable.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePulsatile GH Secretion \u0026amp; IGF-1 Axis Research\u003c\/strong\u003e Like CJC-1295 No DAC, ipamorelin stimulates pulsatile rather than continuous GH secretion. Its half-life of approximately two hours in rodent models — longer than GHRP-6 due to its approximately five-fold lower systemic plasma clearance — produces GH pulses of meaningful duration while preserving the inter-pulse intervals that allow natural somatostatin feedback to operate. Elevated GH secretion drives downstream IGF-1 production, mediated primarily through hepatic GH receptor signalling, and the GH\/IGF-1 axis effects of ipamorelin — including anabolic signalling in skeletal muscle, lipolytic activity in adipose tissue, and effects on bone metabolism — have been studied in multiple preclinical models.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eBone Mineral Density Research\u003c\/strong\u003e Ipamorelin has been studied in models of bone metabolism, with preclinical data demonstrating increases in bone mineral content (BMC) in treated female rats as measured by dual-energy X-ray absorptiometry (DXA) in vivo. Comparative studies examining ipamorelin and GHRP-6 both demonstrated BMC increases, consistent with the known role of the GH\/IGF-1 axis in bone formation, periosteal expansion, and endochondral ossification. These findings have positioned ipamorelin as a tool of interest in preclinical osteoporosis research and models of GH deficiency-associated bone loss.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eGastrointestinal Motility Research\u003c\/strong\u003e The GHS-R1a receptor is expressed not only in the pituitary and hypothalamus but throughout the gastrointestinal tract — reflecting the physiological role of ghrelin as a gut-derived hormone regulating gastric motility and appetite. Ipamorelin has been studied in preclinical models of gastrointestinal dysfunction, including postoperative ileus (POI) — a clinically important condition characterised by delayed gastric emptying following abdominal surgery. Studies by Greenwood-Van Meerveld and colleagues using rodent POI models demonstrated that ipamorelin produced dose-dependent improvements in gastric emptying and reversal of POI-induced delayed gastrointestinal transit, with effects mediated through GHS-R1a expressed in gastrointestinal smooth muscle and enteric nervous system tissue. These findings have expanded ipamorelin's research relevance into gastrointestinal biology beyond its primary GH secretagogue profile.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eBody Composition \u0026amp; Metabolic Research\u003c\/strong\u003e The downstream metabolic effects of ipamorelin-stimulated GH\/IGF-1 axis activation — including GH-mediated lipolysis in adipose tissue, IGF-1-mediated skeletal muscle protein synthesis, and nitrogen retention — have made ipamorelin a useful tool in preclinical body composition research. Studies have examined ipamorelin in models of lean mass accretion, visceral fat reduction, and metabolic syndrome, with findings consistent with the broader GH\/IGF-1 axis literature. Its hormonal selectivity — specifically the absence of cortisol elevation — is a meaningful research advantage in these models, as elevated cortisol has well-documented catabolic effects on muscle tissue that would otherwise confound body composition outcomes.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCombination Research: Ipamorelin + CJC-1295 No DAC (GHRH + GHRP Synergy)\u003c\/strong\u003e One of the most important and widely replicated findings in GH secretagogue research is the synergistic relationship between GHRH-axis peptides and GHRP-class peptides in stimulating GH release. When a GHRH analogue (such as CJC-1295 No DAC) and a GHRP (such as ipamorelin) are administered together, the combined GH release substantially exceeds the sum of the individual responses — a finding consistent with the well-established physiological synergism between the hypothalamic GHRH and ghrelin systems. This occurs because the two compounds act through distinct and mechanistically independent receptors (GHRH-R and GHS-R1a respectively), and their downstream signalling cascades converge synergistically at the level of pituitary somatotroph GH secretion. This combination paradigm — CJC-1295 No DAC paired with ipamorelin — has become one of the most commonly used experimental protocols in preclinical GH-axis research, and both compounds are available in our catalogue to support this research design.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eIpamorelin vs. GHRP-2 and GHRP-6: Selectivity Comparison\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eParameter\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eIpamorelin\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eGHRP-6\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eGHRP-2\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eGH release potency (swine)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eED50 ~2.3 nmol\/kg\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eED50 ~3.9 nmol\/kg\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eED50 ~0.6 nmol\/kg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eGH release efficacy (swine)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eEmax ~65 ng\/mL\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eEmax ~74 ng\/mL\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eEmax ~56 ng\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eACTH\/cortisol elevation\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone (even at 200× ED50)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSignificant\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSignificant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eProlactin\/gonadotropin effects\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePlasma clearance vs GHRP-6\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e~5× lower\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eReference\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLower than GHRP-6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppetite \/ gastric effects\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMild (GHS-R1a mediated)\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSignificant\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThis table illustrates why ipamorelin has become the preferred GHRP for researchers where hormonal specificity and clean pharmacology are experimental priorities — delivering comparable GH release potency to GHRP-6 while eliminating the ACTH and cortisol confounders that complicate interpretation of results with the older compounds.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eIpamorelin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSequence\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAib-His-D-2-Nal-D-Phe-Lys-NH₂\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eClassification\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSelective GHS-R1a agonist \/ GHRP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eC₃₈H₄₉N₉O₅\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e711.85 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile bacteriostatic water or PBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e170851-70-4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our ipamorelin undergoes a comprehensive multi-stage quality control process before release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, non-natural amino acid incorporation (Aib, D-2-Nal, D-Phe), and full pentapeptide sequence accuracy\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe three non-natural amino acids in ipamorelin — Aib, D-2-Nal, and D-Phe — are analytically critical features that distinguish it from related GHRPs. Our MS verification process explicitly confirms their incorporation to ensure the correct compound is delivered with research-grade accuracy and batch-to-batch consistency.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin lyophilised powder should be reconstituted using sterile bacteriostatic water. Inject slowly against the side of the vial and swirl gently — do not vortex. Once reconstituted, aliquot and store at 2–8°C. Use within 28–30 days of reconstitution. The compound exhibits moderate resistance to metabolic degradation in solution, but repeated freeze-thaw cycles should nonetheless be avoided to maintain research-grade integrity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eIpamorelin Within the Research Peptide Catalogue\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIpamorelin occupies the ghrelin receptor agonist \/ GHRP position within our GH-axis research toolkit — mechanistically complementary to, and synergistic with, the GHRH-axis compounds CJC-1295 No DAC and tesamorelin, and distinct from the direct GH replacement approach of rhGH.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWithin the broader catalogue, ipamorelin's GHS-R1a-mediated GH\/IGF-1 axis activity is mechanistically distinct from the tissue-repair focus of BPC-157 and TB-500, the genomic and matrix biology of GHK-Cu, the mitochondrial metabolic signalling of MOTS-c, the systemic triple hormonal agonism of retatrutide, the intracellular NAD+ axis of 5-Amino-1MQ, and the neuropeptide biology of Selank. Our full GH axis research toolkit now comprises three distinct mechanistic entry points: ghrelin receptor agonism (ipamorelin), GHRH receptor agonism (CJC-1295 No DAC, tesamorelin), and direct GH replacement (rhGH) — providing researchers with the tools to study GH biology from upstream secretagogue stimulation through to receptor-level replacement.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides are manufactured to the same \u0026gt;99% purity standard and supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. Ipamorelin is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"5mg","offer_id":59643105542478,"sku":null,"price":15.99,"currency_code":"GBP","in_stock":true},{"title":"10mg","offer_id":59643105575246,"sku":null,"price":29.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/ipamorelin-navy-v2.jpg?v=1781523195"},{"product_id":"mots-c-1","title":"Mots-c","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eMOTS-c | Mitochondrial Open Reading Frame of the 12S rRNA-c | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-Gln-Ala-Val-Thr-Pro-Gly-Gly-Leu-Leu-Leu-Gly-Ala-Pro-Pro-Ile-Pro-Tyr-Arg-Ile-Pro-Ile-Pro-Gly-Ser-Ser-Val-Tyr \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₁₂₁H₂₀₀N₃₄O₃₂ \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 2174.5 g\/mol \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 1627580-64-6\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is MOTS-c?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eMOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded not by the nuclear genome, but by the mitochondrial genome — specifically within the 12S ribosomal RNA gene. It was first identified and characterised by researchers at the University of Southern California in 2015, making it one of the most recently discovered members of a new class of signalling molecules known as mitochondrial-derived peptides (MDPs).\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eThe discovery of MOTS-c fundamentally expanded scientific understanding of mitochondrial biology. Previously regarded primarily as the cell's energy-producing organelles, mitochondria are now understood to function as active endocrine-like signalling centres — capable of producing bioactive peptides that communicate with the nucleus, peripheral tissues, and systemic metabolic systems. MOTS-c is the most extensively studied of these mitochondrial peptides and has rapidly become a subject of considerable scientific interest.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eLike GHK-Cu, circulating MOTS-c levels in humans appear to decline with age, and this pattern has made it a compelling target for researchers studying metabolic ageing, insulin sensitivity, and cellular stress response. Circulating MOTS-c has also been shown to vary with exercise intensity in human subjects — a finding that has accelerated research interest across exercise science and metabolic biology.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur MOTS-c is synthesised under rigorous quality-controlled manufacturing conditions, achieving a verified purity of greater than 99% as confirmed by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). It is supplied as a lyophilised (freeze-dried) powder to ensure maximum stability throughout storage and shipping.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Scientific Interest\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eSince its discovery in 2015, MOTS-c has been the subject of an expanding body of peer-reviewed preclinical literature. Research spans metabolic science, exercise physiology, ageing biology, immunology, and cardiovascular science. Its unique mitochondrial origin and its apparent role as a systemic metabolic regulator distinguish it from all other peptides in this catalogue.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMitochondrial Origin \u0026amp; Retrograde Signalling\u003c\/strong\u003e MOTS-c is translated within the mitochondria from a short open reading frame embedded in the 12S rRNA gene — a region long considered non-coding. Upon synthesis, MOTS-c is exported into the cytoplasm and, under conditions of cellular stress, translocates to the nucleus where it modulates gene expression. This mitochondria-to-nucleus retrograde signalling pathway is a defining feature of MOTS-c biology and a key reason it has attracted substantial mechanistic research interest. It represents a fundamentally new axis of intracellular communication.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eInsulin Sensitivity \u0026amp; Glucose Metabolism\u003c\/strong\u003e The most extensively studied aspect of MOTS-c activity involves glucose metabolism and insulin signalling. Preclinical research in rodent models has demonstrated that MOTS-c administration improves insulin sensitivity and reduces fasting blood glucose in diet-induced obesity models. Studies have identified AMPK (AMP-activated protein kinase) activation as a central mechanism — MOTS-c appears to promote AMPK phosphorylation, thereby enhancing glucose uptake and fatty acid oxidation in skeletal muscle. This positions MOTS-c among the most mechanistically interesting peptides in metabolic research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eExercise Mimicry \u0026amp; Skeletal Muscle Research\u003c\/strong\u003e One of the most striking findings in MOTS-c research is its apparent relationship with physical exercise. Studies have shown that circulating MOTS-c levels rise in response to aerobic exercise in both animal models and human subjects. Furthermore, exogenous MOTS-c administration in sedentary rodent models has produced metabolic adaptations partially overlapping with those induced by exercise — including increased mitochondrial biogenesis markers, improved fat oxidation, and enhanced skeletal muscle glucose utilisation. This has led researchers to describe MOTS-c as a candidate \"exercise mimetic\" peptide, making it a subject of significant interest in metabolic and sports science research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAge-Related Decline \u0026amp; Longevity Research\u003c\/strong\u003e Circulating MOTS-c concentrations decline measurably with age in both animal and human studies, and this age-associated reduction correlates with metabolic deterioration. Conversely, centenarian populations have been observed to maintain relatively higher MOTS-c plasma levels compared to age-matched controls — a finding that has generated substantial interest in longevity research. Preclinical studies in aged mouse models have demonstrated that MOTS-c supplementation can partially restore metabolic function and physical performance, reinforcing its candidacy as a target in ageing biology research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eInflammatory Response \u0026amp; Immune Modulation\u003c\/strong\u003e More recent research has begun to examine MOTS-c's role in immune and inflammatory regulation. Preclinical studies have observed that MOTS-c modulates macrophage activity and attenuates inflammatory cytokine expression — including IL-6 and TNF-α — in models of systemic inflammation. Its role in regulating the innate immune response to metabolic stress is an active and rapidly evolving area of investigation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCardiovascular Research\u003c\/strong\u003e Emerging preclinical evidence suggests MOTS-c may exert cardioprotective effects. Studies in cardiac ischaemia-reperfusion models have observed reduced cardiomyocyte apoptosis and improved mitochondrial function following MOTS-c treatment. Researchers have also noted associations between MOTS-c levels and cardiovascular risk markers in human observational studies, though the mechanistic basis of these associations continues to be investigated.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eBone \u0026amp; Musculoskeletal Research\u003c\/strong\u003e A growing body of literature has examined MOTS-c in the context of bone metabolism. Preclinical studies in ovariectomised rodent models — a standard model for postmenopausal bone loss — have observed that MOTS-c administration attenuates bone density reduction and modulates osteoblast-osteoclast balance. This has expanded MOTS-c research interest into osteoporosis biology and skeletal homeostasis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSequence\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTyr-Gln-Ala-Val-Thr-Pro-Gly-Gly-Leu-Leu-Leu-Gly-Ala-Pro-Pro-Ile-Pro-Tyr-Arg-Ile-Pro-Ile-Pro-Gly-Ser-Ser-Val-Tyr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile water or PBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e1627580-64-6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our MOTS-c is subject to a comprehensive, multi-stage quality control process prior to release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, sequence integrity, and molecular weight\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWe maintain complete batch traceability across synthesis, purification, and testing — providing the consistency researchers require for reproducible experimental results.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eMOTS-c lyophilised powder should be reconstituted using sterile bacteriostatic water or phosphate-buffered saline (PBS). Gently swirl the vial to dissolve — avoid vortexing, which can disrupt peptide structure. Once reconstituted, aliquot immediately into single-use volumes and store at –20°C. Repeated freeze-thaw cycles should be strictly avoided to preserve peptide integrity and biological activity in experimental settings.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should be conducted in compliance with standard laboratory safety protocols and applicable institutional or regulatory requirements.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eMOTS-c Within a Research Peptide Panel\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eMOTS-c occupies a distinct and complementary position within a research peptide panel. While BPC-157 and TB-500 are primarily studied for their roles in tissue repair and wound healing, and GHK-Cu for its influence on gene expression and extracellular matrix remodelling, MOTS-c targets a fundamentally different biological axis — mitochondrial function, systemic metabolism, and cellular energy regulation. Together, these four peptides represent a broad and mechanistically diverse research toolkit, covering tissue repair, inflammation, genomic modulation, and metabolic biology.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides in our catalogue are manufactured to the same \u0026gt;99% purity standard and are supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. MOTS-c is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"10mg","offer_id":59643105640782,"sku":null,"price":28.99,"currency_code":"GBP","in_stock":true},{"title":"40mg","offer_id":59643105673550,"sku":null,"price":58.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/mots-c-navy-v2.jpg?v=1781522930"},{"product_id":"retatrutide","title":"Retatrutide","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eRetatrutide | LY3437943 | GIP\/GLP-1\/Glucagon Triple Receptor Agonist | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAlso Known As:\u003c\/strong\u003e LY3437943 \u003cstrong\u003eMechanism:\u003c\/strong\u003e Triple agonist — GIP, GLP-1, and glucagon receptor \u003cstrong\u003eMolecular Structure:\u003c\/strong\u003e 39-amino acid peptide with C20 fatty diacid moiety \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e –20°C, away from light and moisture \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 2381272-73-5\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is Retatrutide?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eRetatrutide (developmental code: LY3437943) is an investigational synthetic peptide developed by Eli Lilly and Company. It is a first-in-class triple hormone receptor agonist, designed as a single molecule that simultaneously activates three distinct receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG). This multi-receptor mechanism distinguishes retatrutide from earlier generations of incretin-based research compounds — including GLP-1 mono-agonists such as semaglutide, and dual GIP\/GLP-1 agonists such as tirzepatide — by introducing glucagon receptor activation as an additional metabolic axis.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eStructurally, retatrutide is a 39-amino acid peptide conjugated to a C20 fatty diacid moiety, which confers an extended pharmacokinetic half-life suitable for once-weekly dosing in clinical research settings. Compared to endogenous GLP-1 and glucagon, retatrutide demonstrates lower potency at GLP-1 and glucagon receptors but substantially higher potency at the human GIP receptor — a pharmacological profile deliberately engineered to balance efficacy with tolerability.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eRetatrutide has progressed through Phase 2 clinical trials and into the Phase 3 TRIUMPH programme — one of the most significant and closely watched clinical development programmes in metabolic research. It currently represents the most clinically advanced triple hormone receptor agonist in the scientific literature and is among the most actively researched peptides in the field of metabolic and obesity science.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur retatrutide is supplied for research purposes only, synthesised under strict quality-controlled manufacturing conditions and verified to a purity of greater than 99% by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). It is provided as a lyophilised (freeze-dried) powder for maximum stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Clinical Trial Data\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eRetatrutide has one of the most substantive and rapidly evolving clinical research profiles of any peptide currently available for laboratory study. The compound has been evaluated in multiple randomised, placebo-controlled trials and has generated results that have been published in leading peer-reviewed journals including the New England Journal of Medicine, The Lancet, and Nature Medicine.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eTriple Receptor Mechanism of Action\u003c\/strong\u003e Retatrutide's triple agonist mechanism operates across three complementary metabolic pathways. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and promotes insulin secretion in a glucose-dependent manner. GIP receptor activation enhances insulin secretion, modulates adipose tissue metabolism, and appears to synergise with GLP-1 activity to produce greater metabolic effects than either hormone alone — as demonstrated by the clinical performance of the dual agonist tirzepatide. The addition of glucagon receptor agonism introduces a third axis: increased energy expenditure, enhanced hepatic fat oxidation, and PCSK9-mediated reduction in LDL cholesterol. The net result of this triple activation is a broader and potentially more powerful metabolic response than earlier generation single or dual receptor agonists.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePhase 2 Obesity Trial — New England Journal of Medicine (2023)\u003c\/strong\u003e The pivotal Phase 2 obesity trial of retatrutide, published in the New England Journal of Medicine, enrolled 338 adults with obesity (BMI ≥30) or overweight with weight-related comorbidities. Participants received once-weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks. The results were notable even by the elevated standards of the modern incretin era. At 48 weeks, participants on the 8 mg dose achieved a mean body weight reduction of 22.8%, while those on the highest 12 mg dose achieved a mean reduction of 24.2% — compared to just 2.1% in the placebo group. Notably, 100% of participants in both the 8 mg and 12 mg groups achieved at least 5% body weight reduction, with 83% of the 12 mg group achieving reductions of 15% or more. These findings were accompanied by meaningful improvements in cardiometabolic markers including waist circumference, blood pressure, fasting glucose, HbA1c, insulin levels, and lipid profiles.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePhase 2 Type 2 Diabetes Trial — The Lancet (2023)\u003c\/strong\u003e A parallel Phase 2 trial published in The Lancet assessed retatrutide in 281 participants with type 2 diabetes over 36 weeks. At the highest dose of 12 mg, participants achieved mean body weight reduction of 16.9% compared to 3.0% with placebo. Glycaemic outcomes were equally striking: 77–82% of participants on retatrutide achieved euglycaemia (HbA1c ≤6.5%), and between 57–63% achieved body weight reductions of 15% or more. These results were described by lead investigators as the most significant weight loss outcomes reported in a clinical trial for type 2 diabetes at that time.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD\/NASH) — Nature Medicine (2024)\u003c\/strong\u003e A substudy of the Phase 2 obesity trial, published in Nature Medicine, examined retatrutide's effects in participants with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). Results demonstrated substantial reductions in liver fat content at 24 weeks across all active doses, with the 8 mg and 12 mg doses producing mean relative liver fat reductions of 81.4% and 82.4% respectively, compared to a +0.3% change with placebo. At the highest doses, more than 90% of participants achieved normalisation of liver fat — findings of significant interest to researchers working in hepatology and fatty liver disease.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePhase 3 TRIUMPH Programme\u003c\/strong\u003e Retatrutide has now entered the Phase 3 TRIUMPH clinical programme, one of the most expansive trial programmes currently underway in obesity and metabolic medicine. The TRIUMPH programme is evaluating retatrutide across multiple indications including chronic weight management, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and MASLD. In December 2025, Eli Lilly announced positive topline results from TRIUMPH-4 — a 68-week Phase 3 trial in adults with obesity and knee osteoarthritis — in which retatrutide delivered average weight loss of up to 71.2 lbs alongside substantial reductions in osteoarthritis pain. Phase 3 trials across the broader TRIUMPH programme are projected to continue through 2025 and beyond, with regulatory submission timelines dependent on full data readouts.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCardiometabolic Research\u003c\/strong\u003e Beyond weight reduction, retatrutide's glucagon receptor component has attracted research interest for its cardiovascular effects. Phase 2 data demonstrated LDL cholesterol reductions of approximately 20%, a finding researchers have attributed to glucagon agonism-mediated effects on PCSK9 degradation. Reductions in systolic and diastolic blood pressure, triglycerides, and markers of insulin resistance have also been observed, positioning retatrutide as a subject of broad interest across cardiometabolic research.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eRetatrutide (LY3437943)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMechanism\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTriple agonist — GIP \/ GLP-1 \/ glucagon receptors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStructure\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e39-amino acid peptide, C20 fatty diacid conjugate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile water or PBS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e–20°C, keep away from light\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months when stored correctly (lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e2381272-73-5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our retatrutide undergoes a rigorous multi-stage quality control process before release to researchers. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99%\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, fatty acid conjugation integrity, and sequence accuracy\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFull batch traceability is maintained across synthesis, purification, and quality testing, giving researchers the confidence required for reproducible, high-quality experimental work.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eRetatrutide lyophilised powder should be reconstituted using sterile bacteriostatic water or phosphate-buffered saline (PBS). Gently swirl the vial — do not vortex. Once reconstituted, aliquot immediately and store at –20°C. As with all peptide conjugates containing fatty acid moieties, repeated freeze-thaw cycles should be strictly avoided to preserve the structural integrity of the molecule and the reliability of experimental results.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eRetatrutide in Context: How It Compares to Other Research Peptides\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eRetatrutide occupies a distinct position within the broader research peptide landscape. Unlike tissue-focused peptides such as BPC-157 and TB-500, or genomic and matrix-remodelling peptides such as GHK-Cu, retatrutide operates as a hormonal receptor agonist targeting the systemic neuroendocrine regulation of metabolism. Its triple receptor mechanism sets it apart even from other incretin-class research compounds — representing the next evolutionary step beyond semaglutide (GLP-1 mono-agonist) and tirzepatide (GLP-1\/GIP dual agonist) in the hierarchy of metabolic peptide research.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFor researchers building a comprehensive metabolic peptide panel, retatrutide complements MOTS-c — which operates at the mitochondrial and intracellular metabolic level — by providing a systemic hormonal signalling perspective on energy homeostasis and metabolic regulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides in our catalogue are manufactured to the same \u0026gt;99% purity standard and are supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. Retatrutide is an investigational compound and is not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority. It is not a drug, supplement, or food product. This product must not be administered to humans or animals. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"20mg","offer_id":59643105870158,"sku":null,"price":97.99,"currency_code":"GBP","in_stock":true},{"title":"40mg","offer_id":59643105935694,"sku":null,"price":188.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/retatrutide-navy-v2_90f542a1-f711-48af-9f65-11c56ff9674a.jpg?v=1781522523"},{"product_id":"tesamorelin-th9507","title":"Tesamorelin (TH9507) Peptide","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eTesamorelin | TH9507 | Stabilised Growth Hormone-Releasing Hormone Analogue | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAlso Known As:\u003c\/strong\u003e TH9507, Egrifta (pharmaceutical brand name) \u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu (44 residues, N-terminally modified) \u003cstrong\u003eModification:\u003c\/strong\u003e Trans-3-hexenoic acid moiety conjugated to N-terminal tyrosine residue \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₂₂₁H₃₆₆N₇₂O₆₇S \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 5135.77 g\/mol \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e 2–8°C (refrigerated); –20°C for long-term storage \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 218949-48-5\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is Tesamorelin?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin (developmental code: TH9507; brand name Egrifta) is a synthetic 44-amino acid analogue of endogenous human growth hormone-releasing hormone (GHRH), developed by Theratechnologies Inc. and approved by the U.S. Food and Drug Administration (FDA) in 2010 — making it one of the very few research-grade peptides with full FDA approval and an extensive human clinical trial dataset behind it.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEndogenous GHRH is a 44-amino acid hypothalamic peptide that binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the synthesis and pulsatile secretion of growth hormone (GH). While native GHRH is pharmacologically active, it is rapidly degraded in vivo by the serum enzyme dipeptidyl peptidase-4 (DPP-4) — which cleaves at the Tyr-Ala bond at the N-terminus — resulting in a biological half-life of only a few minutes and rendering it largely unsuitable as a sustained research tool.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin addresses this limitation through a precise structural modification: conjugation of a trans-3-hexenoic acid moiety to the N-terminal tyrosine residue. This hydrophobic modification sterically protects the DPP-4 cleavage site, producing a compound with significantly enhanced metabolic stability while retaining full agonist activity at the GHRH receptor. The result is a peptide that reproduces the physiological pulsatile pattern of GH secretion — preserving the natural hypothalamic-pituitary feedback architecture — rather than delivering continuous, supraphysiological GH exposure as exogenous rhGH administration does. This key distinction has major implications for research design and for the safety and hormonal specificity profile of tesamorelin relative to direct GH administration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur tesamorelin is synthesised under strict quality-controlled manufacturing conditions, verified to a purity of greater than 99% by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS), and supplied as a lyophilised (freeze-dried) powder for optimal stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Clinical Data\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin carries one of the most extensive and rigorously validated clinical research profiles of any peptide available for laboratory study. It has been evaluated in large-scale, randomised, double-blind, placebo-controlled Phase III trials involving over 800 participants, with findings published in leading peer-reviewed journals. This level of clinical evidence is exceptional within the research peptide landscape and makes tesamorelin a uniquely robust reference compound for the GH\/IGF-1 axis.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMechanism: GHRH Receptor Activation \u0026amp; Pulsatile GH Secretion\u003c\/strong\u003e Tesamorelin binds with high affinity to the growth hormone-releasing hormone receptor (GHRH-R) — a G-protein-coupled receptor expressed predominantly on somatotroph cells of the anterior pituitary. Receptor binding activates the adenylate cyclase–cAMP–PKA intracellular signalling cascade, promoting both acute GH release and longer-term GH gene transcription. Critically, this mechanism preserves the natural pulsatile pattern of GH secretion and maintains hypothalamic-pituitary IGF-1 feedback inhibition — meaning GH release remains physiologically regulated rather than driven to sustained supraphysiological levels. Downstream, elevated GH stimulates hepatic and peripheral production of IGF-1 and IGF binding protein-3 (IGFBP-3), which mediate the compound's anabolic, lipolytic, and tissue-remodelling effects at target tissues.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePulsatile GH Augmentation — Clinical Study in Healthy Males\u003c\/strong\u003e A landmark mechanistic study published in the Journal of Clinical Endocrinology \u0026amp; Metabolism examined the effects of tesamorelin at 2 mg daily for two weeks in 13 healthy males. Tesamorelin significantly increased mean overnight GH, average GH peak area, and basal GH secretion. IGF-1 increased by 181 ± 22 μg\/litre (P \u0026lt; 0.0001), while neither fasting glucose nor insulin-stimulated glucose uptake was significantly affected — an important finding demonstrating that tesamorelin's GH stimulation can substantially elevate IGF-1 without impairing peripheral insulin sensitivity, a key differentiator from direct exogenous rhGH administration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePhase III Clinical Trials: HIV-Associated Lipodystrophy (LIPO-010 \u0026amp; CTR-1011)\u003c\/strong\u003e The pivotal Phase III evidence base for tesamorelin comprises two large, multicentre, randomised, double-blind, placebo-controlled trials — LIPO-010 (n=412) and CTR-1011 (n=404) — enrolling a combined total of 816 HIV-infected patients with excess visceral adiposity associated with antiretroviral therapy. Across both trials, tesamorelin demonstrated consistent reductions in visceral adipose tissue (VAT) of approximately 15–20%, accompanied by improvements in triglycerides, waist circumference, and patient-reported body image outcomes. These results were robust, reproducible across both trials, and formed the basis of the compound's FDA approval in 2010 as the first and only medication specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. An important finding from these trials was that tesamorelin significantly reduced visceral adipose tissue without adversely affecting subcutaneous fat or inducing insulin resistance — a clinically meaningful distinction from direct GH therapy.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eNAFLD \u0026amp; Liver Fat Research — The Lancet HIV\u003c\/strong\u003e Beyond visceral fat reduction, tesamorelin has been studied in models of metabolic dysfunction-associated liver disease. Tesamorelin is also being evaluated as therapy for insulin resistance, obesity, and nonalcoholic fatty liver disease. In a substudy examining HIV-positive participants with NAFLD, tesamorelin produced clinically meaningful reductions in liver fat content and, in some analyses, attenuation of fibrosis progression markers — findings of significant interest to researchers working in hepatology and liver metabolic disease.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCardiovascular Research\u003c\/strong\u003e In a study of tesamorelin (2 mg\/day subcutaneously) in 60 abdominally obese volunteers with reduced peak GH stimulation, 12 months of treatment significantly decreased carotid intima-media thickness (cIMT), VAT, C-reactive protein, and triglycerides compared to placebo. Reductions in cIMT — a validated surrogate marker of coronary atherosclerosis — are of particular interest to cardiovascular researchers, though the relative contributions of IGF-1 elevation, VAT reduction, and anti-inflammatory effects to this outcome continue to be investigated.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCognitive \u0026amp; Neuroendocrine Research\u003c\/strong\u003e An emerging and scientifically compelling area of tesamorelin research concerns cognitive function and neuroendocrine biology. Given the well-established role of the GH\/IGF-1 axis in hippocampal neurogenesis, synaptic plasticity, and neuroprotection — and the progressive decline of GH secretion with age — tesamorelin has been investigated as a research tool for examining GH-mediated cognitive effects. Studies have explored tesamorelin's influence on verbal memory, executive function, and brain amyloid-beta metabolism in older adults, with findings suggesting a potential role for the GH\/IGF-1 axis in age-related cognitive trajectories that merits continued investigation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMetabolic Syndrome \u0026amp; Insulin Resistance Research\u003c\/strong\u003e Beyond the HIV-lipodystrophy indication, researchers have studied tesamorelin in broader models of visceral obesity and metabolic syndrome. Tesamorelin's stimulation of pulsatile GH release is thought to preferentially target visceral adipose tissue, suppress hepatic lipogenesis, and improve body-composition biomarkers. Its selectivity for visceral over subcutaneous fat — a pattern consistent with the physiological role of pulsatile GH in fat distribution — makes tesamorelin a valuable tool for researchers seeking to dissect the specific metabolic consequences of visceral adiposity and GH axis dysregulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAgeing \u0026amp; Somatopause Research\u003c\/strong\u003e The progressive decline in GH secretion with age — somatopause — is associated with increased visceral adiposity, reduced lean mass, impaired bone density, and deteriorating metabolic parameters. Tesamorelin's capacity to restore more youthful pulsatile GH dynamics without bypassing natural feedback mechanisms makes it an important research tool for studying somatopause-related metabolic changes and the role of the GH axis in healthy ageing trajectories. Unlike exogenous rhGH, which replaces GH directly and suppresses endogenous secretion, tesamorelin stimulates the pituitary — preserving the regulatory architecture while augmenting output.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eTesamorelin vs. Exogenous rhGH: A Key Research Distinction\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eA critical consideration for researchers choosing between tesamorelin and recombinant human growth hormone (rhGH) is the fundamentally different hormonal environment each creates. Direct rhGH administration delivers continuous, non-pulsatile GH exposure that can suppress endogenous GH secretion via negative feedback and frequently drives IGF-1 to supraphysiological levels — increasing the risk of insulin resistance and other GH excess effects. Tesamorelin, by contrast, stimulates the pituitary to release GH in the natural pulsatile pattern, maintains hypothalamic-pituitary feedback integrity, and produces more physiological IGF-1 elevation. This distinction is experimentally important: researchers studying the consequences of physiological versus supraphysiological GH axis activity, or seeking to model GH restoration without disrupting endocrine homeostasis, will find tesamorelin and rhGH produce meaningfully different experimental conditions that must be accounted for in protocol design.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBoth tesamorelin and rhGH are available in our catalogue, allowing researchers to select the most appropriate tool for their specific experimental model.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTesamorelin (TH9507)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eClassification\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStabilised GHRH analogue — 44-amino acid polypeptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eN-terminal Modification\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTrans-3-hexenoic acid (DPP-4 protection)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eC₂₂₁H₃₆₆N₇₂O₆₇S\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5135.77 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile water or bacteriostatic water\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e2–8°C (short-term); –20°C (long-term, lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months lyophilised; use reconstituted solution within 28 days (2–8°C)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e218949-48-5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our tesamorelin undergoes a comprehensive multi-stage quality control process before release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99% and correct modification profile\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, N-terminal hexenoyl modification integrity, and full 44-residue sequence accuracy\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eSDS-PAGE\u003c\/strong\u003e — confirms correct molecular weight profile under denaturing conditions\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFull batch traceability is maintained across synthesis, purification, and quality testing. The N-terminal modification is an analytically critical feature of tesamorelin that requires specific MS verification — our QC process explicitly confirms hexenoyl conjugation integrity to ensure research-grade reliability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin lyophilised powder should be reconstituted by gently adding sterile bacteriostatic water to the side of the vial — not directly onto the powder. Swirl gently until fully dissolved; do not vortex. Once reconstituted, aliquot immediately and store at 2–8°C for short-term use (within 28 days) or at –20°C in lyophilised form for long-term storage. Avoid repeated freeze-thaw cycles to preserve the integrity of the N-terminal modification and peptide structure.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAs a larger modified peptide, tesamorelin shares some storage sensitivity characteristics with rhGH and should be handled with the same care given to other complex peptide research compounds. All handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eTesamorelin Within the Research Peptide Catalogue\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin occupies a distinctive position within our catalogue as the only GHRH-axis upstream secretagogue — acting at the level of the hypothalamic-pituitary interface to stimulate endogenous GH production, rather than delivering GH directly as rhGH does. This upstream mechanism complements rhGH by allowing researchers to study pituitary-mediated GH secretion and the effects of physiological GH pulsatility, in contrast to the non-pulsatile exogenous GH exposure that rhGH produces.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWithin the broader metabolic research landscape of the catalogue, tesamorelin's GH\/IGF-1 axis activity is mechanistically distinct from — and complementary to — the systemic triple hormone receptor agonism of retatrutide, the mitochondrial AMPK signalling of MOTS-c, and the intracellular NAD+ axis of 5-Amino-1MQ. Researchers studying visceral adiposity, metabolic ageing, or body composition from multiple mechanistic angles will find tesamorelin provides a physiological hormonal signalling perspective that is not replicated by any other compound in the catalogue.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides in our catalogue are manufactured to the same \u0026gt;99% purity standard and are supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. While tesamorelin (Egrifta) holds FDA approval for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, this research-grade product is not supplied for therapeutic use and must not be administered to humans or animals outside of appropriately authorised and supervised clinical contexts. It is not a supplement or food product. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"5mg","offer_id":59643106165070,"sku":null,"price":31.99,"currency_code":"GBP","in_stock":true},{"title":"10mg","offer_id":59643106197838,"sku":null,"price":58.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/tesamorelin-navy-v2.jpg?v=1781522169"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/collections\/hf_20260526_183844_d8b5751f-6e39-473e-b4e0-480c0858c2d5.png?v=1780245162","url":"https:\/\/checkout.nexyralab.com\/collections\/immunity-detox.oembed","provider":"Nexyralab.com","version":"1.0","type":"link"}